To review data on acute myeloid leukemia (AML) presented at the 2017 meeting of the American Society of Hematology (ASH) and to discuss these data within the framework of future developments for the disease.
Results and conclusion
Data generated by next generation sequencing (NGS) may be used for primary diagnosis, therapy selection and monitoring as well as characterization of persons at risk for AML development. After validation, this method will need to be implemented in general practice in the future. For treatment more targeted therapies—single agent or in combination with standard chemotherapy or low-dose treatment approaches—will become available and complement our armamentarium against AML. Among others interesting targets discussed are FLT-3, IDH1 and 2, BCL-2, MEK, E‑selectin, MDM2 and JAK1. Furthermore, maintenance after induction chemotherapy is again being considered for the management of AML.